• 1
    Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 41528.
  • 2
    Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005; 5: 22331.
  • 3
    Suzuki H, Gabrielson E, Chen W et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002; 31: 14119.
  • 4
    Liang G, Gonzales FA, Jones PA, Orntoft TF, Thykjaer T. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine. Cancer Res 2002; 62: 9616.
  • 5
    Yamashita K, Upadhyay S, Osada M et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002; 2: 48595.
  • 6
    Sato N, Fukushima N, Maitra A et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003; 63: 373542.
  • 7
    Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005; 65: 421827.
  • 8
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74108.
  • 9
    Ushijima T, Sasako M. Focus on gastric cancer. Cancer Cell 2004; 5: 1215.
  • 10
    Kaneda A, Kaminishi M, Yanagihara K, Sugimura T, Ushijima T. Identification of silencing of nine genes in human gastric cancers. Cancer Res 2002; 62: 664550.
  • 11
    Kaneda A, Wakazono K, Tsukamoto T et al. Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers. Cancer Res 2004; 64: 641015.
  • 12
    Ge X, Yamamoto S, Tsutsumi S et al. Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005; 86: 12741.
  • 13
    Murai M, Toyota M, Suzuki H et al. Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer. Clin Cancer Res 2005; 11: 10217.
  • 14
    Lee YY, Kang SH, Seo JY et al. Alterations of p16INK4A and p15INK4B genes in gastric carcinomas. Cancer 1997; 80: 188996.
  • 15
    Satoh A, Toyota M, Itoh F et al. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 2003; 63: 860613.
  • 16
    Chan AS, Tsui WY, Chen X et al. Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma. Oncogene 2003; 22: 694653.
  • 17
    Esteller M, Guo M, Moreno V et al. Hypermethylation-associated inactivation of the cellular retinol-binding-protein 1 gene in human cancer. Cancer Res 2002; 62: 59025.
  • 18
    Li QL, Ito K, Sakakura C et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002; 109: 11324.
  • 19
    Kang GH, Lee S, Kim JS, Jung HY. Profile of aberrant CpG island methylation along the multistep pathway of gastric carcinogenesis. Lab Invest 2003; 83: 63541.
  • 20
    Yustein AS, Harper JC, Petroni GR, Cummings OW, Moskaluk CA, Powell SM. Allelotype of gastric adenocarcinoma. Cancer Res 1999; 59: 143741.
  • 21
    Kim KM, Kwon MS, Hong SJ et al. Genetic classification of intestinal-type and diffuse-type gastric cancers based on chromosomal loss and microsatellite instability. Virchows Arch 2003; 443: 491500.
  • 22
    Choi SW, Park SW, Lee KY, Kim KM, Chung YJ, Rhyu MG. Fractional allelic loss in gastric carcinoma correlates with growth patterns. Oncogene 1998; 17: 26559.
  • 23
    Weiss MM, Kuipers EJ, Postma C et al. Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. Cell Oncol 2004; 26: 30717.
  • 24
    Costello JF, Fruhwald MC, Smiraglia DJ et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000; 24: 1328.
  • 25
    Ushijima T, Watanabe N, Shimizu K, Miyamoto K, Sugimura T, Kaneda A. Decreased fidelity in replicating CpG methylation patterns in cancer cells. Cancer Res 2005; 65: 1117.
  • 26
    Sunaga N, Miyajima K, Suzuki M et al. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res 2004; 64: 427785.
  • 27
    Wiechen K, Diatchenko L, Agoulnik A et al. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol 2001; 159: 163543.
  • 28
    Hanafusa T, Yumoto Y, Nouso K et al. Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett 2002; 176: 14958.
  • 29
    Komatsu S, Okazaki Y, Tateno M et al. Methylation and downregulated expression of mac25/insulin-like growth factor binding protein-7 is associated with liver tumorigenesis in SV40T/t antigen transgenic mice, screened by restriction landmark genomic scanning for methylation (RLGS-M). Biochem Biophys Res Commun 2000; 267: 10917.
  • 30
    Toyota M, Ho C, Ahuja N et al. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 1999; 59: 230712.
  • 31
    Abdollahi A, Pisarcik D, Roberts D, Weinstein J, Cairns P, Hamilton TC. LOT1 (PLAGL1/ZAC1), the candidate tumor suppressor gene at chromosome 6q24-25 is epigenetically regulated in cancer. J Biol Chem 2003; 278: 60419.
  • 32
    Bilanges B, Varrault A, Basyuk E et al. Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors. Oncogene 1999; 18: 397988.
  • 33
    Xing RH, Rabbani SA. Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: role of DNA methylation. Int J Cancer 1999; 81: 44350.
  • 34
    Pakneshan P, Xing RH, Rabbani SA. Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo. Faseb J 2003; 17: 10818.
  • 35
    Kwong J, Lo KW, Shuk-Nga Chow L et al. Epigenetic silencing of cellular retinol-binding proteins in nasopharyngeal carcinoma. Neoplasia 2005; 7: 6774.
  • 36
    Mazieres J, He B, You L et al. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 2004; 64: 471720.
  • 37
    Hagihara A, Miyamoto K, Furuta J et al. Identification of 27 5′ CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. Oncogene 2004; 23: 870510.
  • 38
    Wang W, Huper G, Guo Y, Murphy SK, Olson JA Jr, Marks JR. Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer. Oncogene 2005; 24: 270514.
  • 39
    Callahan CA, Ofstad T, Horng L et al. MIM/BEG4, a sonic hedgehog-responsive gene that potentiates Gli-dependent transcription. Genes Dev 2004; 18: 27249.
  • 40
    Lee YG, Macoska JA, Korenchuk S, Pienta KJ. MIM, a potential metastasis suppressor gene in bladder cancer. Neoplasia 2002; 4: 2914.
  • 41
    Yang S, Zhong C, Frenkel B, Reddi AH, Roy-Burman P. Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res 2005; 65: 576977.
  • 42
    Butt AJ, Firth SM, King MA, Baxter RC. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem 2000; 275: 39 174–81.